Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280884 | 1.00 | BCHE (0.46) | BCHEACHEPTPN1CTSLCTSB | |
| SCHEMBL4852218 | 0.92 | CAPN1 (0.50) | BCHEACHEPTPN1CTSLCTSB | |
| SCHEMBL4849921 | 0.91 | BCHE (0.45) | BCHEACHEPTPN1TNFRSF1ACA1 | |
| SCHEMBL4856242 | 0.91 | BCHE (0.45) | BCHEACHECTSLCTSBTNFRSF1A | |
| SCHEMBL4853736 | 0.91 | BCHE (0.52) | BCHEACHETNFRSF1A | |
| SCHEMBL6386830 | 0.90 | ABCG2 (0.52) | BCHEACHEPTPN1TNFRSF1AABCG2 | |
| SCHEMBL14306898 | 0.88 | DPP4 (0.47) | BCHEPTPN1CTSLCTSBTNFRSF1A | |
| SCHEMBL4847749 | 0.87 | ACHE (0.42) | BCHEACHETNFRSF1A | |
| SCHEMBL4881624 | 0.85 | PTPN1 (0.44) | BCHEPTPN1CTSLCTSBTNFRSF1A | |
| SCHEMBL4881621 | 0.85 | PTPN1 (0.44) | BCHEPTPN1CTSLCTSBTNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423181-B2 | in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone | LICA PHARMACEUTICALS A/S (DK) | 2008-09-09 | — | — | US | disclosed |
| US-20080027075-A1 | Quaternary Amino-Function Chalcones | LICA PHARMACEUTICALS A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| US-20050227990-A1 | Aminoalkoxy-functional chalcones | LICA PHARMACEUTICALS A/S (DK) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027075-A1 | Quaternary Amino-Function Chalcones | NR2E1, BET1, NR0B1 | BCHE 3286/4885ACHE 4322/4885PTPN1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.